Vertex Pharmaceuticals Incorporated company logo

# 1st Gen Model Vertex Pharmaceuticals Incorporated Pharmaceutical preparations

Subscribe >> Deal exit on
Oct. 23, 2017
Deal entry on
Oct. 23, 2017
0.08%Expected margin
62.30% successful of 61 deals
$154.63 Last close price
at 20-oct-2017

VRTX

Model's trade recommendations -0.86% Return for period

1.42% Annual return

$38.99B Market Cap

β 1.73  

VRTX

Model (following trade recommendations)

VRTX

Underlying stock

S&P 500

Index
Return for period -0.86%
3.71%
1.78%
52wk return 14.96%
91.47%
16.82%
52wk Range
72.02—166.11
2000.54—2399.63
Sortino ratio 0.21
Sharpe ratio 0.16
Norm. RMSE 0.28%
Downside risk 15.01%
Volatility 20.06%
  • STRONG BUY Analysts consensus recommendation

Vertex Pharmaceuticals Inc. discovers, develops and markets small molecule drugs that address major unmet medical needs. The company has eight drug candidates in clinical development to treat viral diseases, inflammation, cancer, autoimmune diseases and neurological disorders. Vertex has created its pipeline using a proprietary information-based approach to drug design that integrates multiple technologies in biology, chemistry and biophysics aimed at increasing the speed and success rate of drug discovery. (PRESS RELEASE)

Industry sector: Medical

Sector classification: Pharmaceutical preparations

Deep Learning based analysis and prediction model for Vertex Pharmaceuticals Incorporated (VRTX) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since Sept. 30, 2015.

Market data for VRTX model training are being downloaded from the Quandl premium datasets on a daily basis.

Model is being retrained on a daily basis.

Float 248M
P/E 572.70
Shares Outstanding 252M
% Held by Insiders 1.80%
% Held by Institutions 92.93%
EPS (last reported FY) $-0.11
EPS (last reported Q) $0.10
EPS, estimated (last reported Q) $0.06
Total revenues $2 B
Net income $-0 B